The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 4, 1999, Pages 615-621

  Gawchik, Sandra M ^a   Saccar, Consuelo L ^b   Noonan, Michael ^b   Reasner, David S ^b   DeGraw, Sidney S ^b  

^a Asthma and Allergy Associates   (United States)

^b NONE

Author keywords

Asthma; Bronchodilator; FEV1; Inhalation solution; Levalbuterol; Pediatric; R albuterol; Racemic albuterol; S albuterol; 2 Agonist

Indexed keywords

LEVALBUTEROL; PLACEBO; SALBUTAMOL; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEBULIZATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACEMIC MIXTURE;

EID: 0033056771     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70233-2     Document Type: Article

References (27)

1. 1. Bakale RP, Wald SA, Butler HT, et al. Albuterol. Clin Rev Allergy Immunol 1996;14:7-36.
2. 2. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971;14:895-9.
3. 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45.
4. 4. Yamaguchi H, McCullough J. S-Albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol 1996;14:47-55.
5. 5. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. S-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998;53:347-54.
6. 6. Johansson F, Rydberg I, Aberg G, Andersson RGG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996;14:57-64.
7. 7. Perrin-Fayolle M, Blum P, Morley J, Grosclaude M, Chambe M. Differential responses of asthmatic airways to enantiomers of albuterol. Clin Rev Allergy Immunol 1996;14:139-47.
8. 8. Nelson H, Bensch G, Pleskow W, et al. Improved bronchodilation with levalbuterol compared to racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943-52.
9. 9. Polgar G, Promodhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders; 1971. p. 272.
10. 10. Jones B, Kenward M. Design and analyses and for three or more treatments: design and analysis of cross-over trials. New York: Chapman & Hall; 1990. p. 189-241.
11. 11. Crapo R, Hankinson J, Irvin C. Standardization of spirometry. Am J Respir Crit Care Med 1995;152:1107-36.
12. 12. Oberklaid F, Mellis C, Le Souef P, Geelhoed G, Maccarrone A. A comparison of a bodyweight dose versus a fixed dose of nebulised salbutamol in acute asthma in children. Med J Aust 1993;158:751-3.
13. 13. Penna AC, Dawson KP. Nebulized salbutamol (albuterol): systemic absorption could be important in achieving bronchodilatation. J Asthma 1993;30:105-7.
14. 14. Schuh S, Reider M, Canny G, et al. Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics 1990;86:509-13.
15. 15. Walle T, Eaton EA, Walle UK, Pesola G. Stereoselective metabolism of RS-albuterol in humans. Clin Rev Allergy Immunol 1996;14:101-13.
16. 16. Tan YK, Soldin SJ. Analysis of S-albutamol enantiomers in human urine by chiral high-performance chromatography and preliminary studies related to the stereoselective disposition kinetics in man. J Chromatogr 1987;422:187-95.
17. 17. Gumbhir-Shah K, Kellerman D, DeGraw S, Koch P, Jusko W. Pharmacokinetic-pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998 (in press).
18. 18. Boulton D, Kawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996;41:35-40.
19. 19. Auclair B, Fried K, Wainer I, Jerussi T, Koch P, Ducharme M. A population analysis of nebulised R-albuterol in dogs using a novel mixed gutlung absorption PK-PD model [abstract]. FASEB J 1998;12:A142.
20. 20. Fried K, Koch P, Wainer I. Determination of the enantiomers of albuterol in human and canine plasma by enantioselective high-performance liquid chromatography on a teicoplanin-based chiral stationary phase. Chirality 1998;10:484-91.
21. 21. Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83:513-8.
22. 22. Bannister O. The effectiveness of nebulized salbutamol in the management of acute asthma in children. Physiotherapy 1980;66:144-6.
23. 23. Groggins R, Milner A, Stokes G. Bronchodilator effects of clemastine, ipratropium bromide, and salbutamol in preschool children with asthma. Arch Dis Child 1981;56:342-4.
24. 24. Blackhall M, Dauth M, Mahoney M, O'Donnell S, Inhalation of fenoterol (berotec) by asthmatic children: a clinical comparison with salbutamol, orciprenaline and isoprenaline. Med J Aust 1976;2:439-44.
25. 25. Hughes D, Mindorff C, Levison H. The immediate effect of sodium cromoglycate on the airway. Ann Allergy 1982;48:6-8.
26. 26. Wolfe J, Shapiro G, Ratner P, et al. Comparison of albuterol and melaprolerenol syrup in the treatmenl of childhood asthma. Pediatrics 1991;88:312-9.
27. 27. Kemp J, Furukawa C, Bronsky E, et al. Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. J Allergy Clin Immunol 1989;83:697-702.